Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation

Chloé Pasin, Irène Balelli, Thierry Van Effelterre, Viki Bockstal, Laura Solforosi, Mélanie Prague, Macaya Douoguih, Rodolphe ThiébautJournal of Virology 2019 · DOI

TL;DR

This study uses a mathematical model to analyze antibody responses to a prime-boost Ebola vaccine, revealing that long-lived antibody-producing cells are crucial for sustained immunity, with half potentially persisting for over 5 years. While vaccine regimens influence early responses, geographic region appears to be a significant factor in long-term antibody levels, with European participants showing higher persistence.

What Problem Does This Paper Address?

The development of effective Ebola vaccines is critical, especially following the devastating 2014-2016 epidemic. Heterologous prime-boost strategies, combining different vaccine vectors like Ad26.ZEBOV and MVA-BN-Filo, are promising for inducing robust and durable immune responses. However, understanding the long-term dynamics of these responses, including how long antibodies persist and what factors influence this persistence, is crucial for vaccine efficacy and deployment. Specifically, this paper aims to quantify the humoral immune response over time after a prime-boost vaccination, estimate the durability of this response, and identify sources of variability, such as vaccine regimen and geographic location.

Methods

The researchers employed a mechanistic mathematical model based on ordinary differential equations (ODEs) to describe the dynamics of the humoral immune response. This model incorporates two distinct populations of antibody-secreting cells (ASCs): short-lived (SL) and long-lived (LL). The model tracks the decay of these ASC populations and their antibody production, as well as the decay of the antibodies themselves. A population approach was used to estimate the model parameters from data collected in three phase 1 clinical trials. This approach allows for the estimation of average parameter values across the study population while also accounting for inter-individual variability and the influence of covariates like vaccine regimen and geographic region. Sensitivity analyses were conducted to assess the robustness of the parameter estimations.

Datasets

The study utilized data from 177 participants in three randomized, observer-blind, placebo-controlled phase 1 trials (EBOVAC1 Consortium) conducted in the United Kingdom, Kenya, Tanzania, and Uganda. These participants received a prime-boost vaccination with either Ad26.ZEBOV and MVA-BN-Filo. Immunogenicity measurements, specifically IgG binding antibody concentrations against the Ebola virus glycoprotein (GP), were collected using ELISA at multiple time points up to one year post-prime immunization. Cellular immune response data (CD4+ T cell cytokine production) was also analyzed.

Key Insights and Ideas

  • Two distinct antibody-producing cell populations are key: The model's success hinges on distinguishing between short-lived ASCs that drive early, transient antibody production and long-lived ASCs that are responsible for sustained antibody levels.
  • Long-lived ASCs are the guardians of long-term immunity: The persistence of antibody levels for years is attributed to these LL ASCs, suggesting that their longevity is a critical factor in vaccine effectiveness over extended periods.
  • Geographic location matters for long-term immunity: A surprising finding is that European participants exhibited significantly higher long-term antibody concentrations compared to East African participants, even though initial peak responses were similar. This suggests that factors beyond the vaccine itself influence how long antibodies persist.
  • Vaccine regimen impacts the peak, not the plateau: While different prime-boost schedules and sequences affect the initial antibody peak, they do not appear to significantly alter the long-term antibody persistence driven by LL ASCs.

Key Results

  • Long-lived ASC half-life: The model estimated that half of the long-lived ASCs could persist for at least 5 years, providing a lower bound for long-term antibody durability.
  • Antibody half-life: The estimated half-life of circulating antibodies was around 24 days, consistent with biological expectations.
  • Vaccine regimen effects: The vaccine regimen significantly influenced the short-lived ASCs and the peak antibody response, but not the long-term antibody persistence.
  • Geographic differences: European subjects showed statistically significantly higher antibody concentrations one year after prime immunization compared to East African subjects. This difference was attributed to variations in the LL ASC compartment dynamics, with European subjects exhibiting higher long-term antibody persistence.
  • Cellular response correlation: The observed differences in long-term antibody levels between geographic regions could not be explained by differences in the measured cellular immune responses (CD4+ T cell cytokine production).

Limitations and Future Work

The authors acknowledge several limitations:

  • Immune memory not explicitly modeled: The current model does not explicitly account for the development of immune memory, which could influence responses to subsequent exposures.
  • Assumption of ASC decay: The assumption that both SL and LL ASC populations decay from 7 days post-boost might influence the estimation of SL ASC half-life, though it's supported by experimental data.
  • Limited data duration: Data was collected for up to one year post-prime immunization, which limits the precise estimation of the half-life of LL ASCs, particularly their upper bound. More data beyond one year would improve this estimation.
  • Small sample size: The study is based on phase 1 trials, meaning the sample size is relatively small, which can affect the precision of parameter estimations.
  • Lack of plasmablast data: The absence of direct measurements of plasmablasts limits a more complete understanding of early antibody dynamics.

Future work suggested includes:

  • Utilizing phase 2 data: Additional data from larger phase 2 studies would help confirm the robustness of the long-term response findings.
  • Investigating geographic differences: Further mechanistic studies are needed to pinpoint the specific factors contributing to the observed geographic differences in antibody persistence.
  • Exploring other factors: Investigating the impact of other factors, such as malaria coinfection, on immune responses could provide further insights.
  • Refining LL ASC half-life estimation: Collecting data beyond one year post-immunization is crucial for a more precise estimation of LL ASC half-lives.

Summary updated

Abstract

The Ebola vaccine based on Ad26.ZEBOV/MVA-BN-Filo prime-boost regimens is being evaluated in multiple clinical trials. The long-term immune response to the vaccine is unknown, including factors associated with the response and variability around the response. We analyzed data from three phase 1 trials performed by the EBOVAC1 Consortium in four countries: the United Kingdom, Kenya, Tanzania, and Uganda. Participants were randomized into four groups based on the interval between prime and boost immunizations (28 or 56 days) and the sequence in which Ad26.ZEBOV and MVA-BN-Filo were administered. Consecutive enzyme-linked immunosorbent assay (ELISA) measurements of the IgG binding antibody concentrations against the Kikwit glycoprotein (GP) were available for 177 participants to assess the humoral immune response up to 1 year postprime. Using a mathematical model for the dynamics of the humoral response, from 7 days after the boost immunization up to 1 year after the prime immunization, we estimated the durability of the antibody response and the influence of different factors on the dynamics of the humoral response. Ordinary differential equations (ODEs) described the dynamics of antibody response and two populations of antibody-secreting cells (ASCs), short-lived (SL) and long-lived (LL). Parameters of the ODEs were estimated using a population approach. We estimated that half of the LL ASCs could persist for at least 5 years. The vaccine regimen significantly affected the SL ASCs and the antibody peak but not the long-term response. The LL ASC compartment dynamics differed significantly by geographic regions analyzed, with a higher long-term antibody persistence in European subjects. These differences could not be explained by the observed differences in cellular immune response.<b>IMPORTANCE</b> With no available licensed vaccines or therapies, the West African Ebola virus disease epidemic of 2014 to 2016 caused 11,310 deaths. Following this outbreak, the development of vaccines has been accelerated. Combining different vector-based vaccines as heterologous regimens could induce a durable immune response, assessed through antibody concentrations. Based on data from phase 1 trials in East Africa and Europe, the dynamics of the humoral immune response from 7 days after the boost immunization onwards were modeled to estimate the durability of the response and understand its variability. Antibody production is maintained by a population of long-lived cells. Estimation suggests that half of these cells can persist for at least 5 years in humans. Differences in prime-boost vaccine regimens affect only the short-term immune response. Geographical differences in long-lived cell dynamics were inferred, with higher long-term antibody concentrations induced in European participants.
BibTeX
@article{pasin2019dynamics,
  author = {Chloé Pasin and Irène Balelli and Thierry Van Effelterre and Viki Bockstal and Laura Solforosi and Mélanie Prague and Macaya Douoguih and Rodolphe Thiébaut},
  title = {{Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation}},
  journal = {Journal of Virology},
  year = {2019},
  doi = {10.1128/jvi.00579-19},
}
Figure